A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs SB 509 (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- 07 Dec 2011 Actual patient number chnaged from 45 to 91 as reported by ClinicalTrials.gov record.
- 22 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2010 Interim results in 30 patients reported at 70th Annual Scientific Sessions of the American Diabetes Association (ADA), according to a Sangamo media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History